Drug/Small Molecule:
olanzapine

last updated 08/10/2011

Dutch Pharmacogenetics Working Group Guideline for olanzapine and CYP2D6

Summary

There are currently no dosing recommendations for olanzapine based on CYP2D6 genotype.

Annotation

The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for olanzapine based on CYP2D6 genotype (PMID:21412232). They do not provide dosing recommendations at this time.

Phenotype (Genotype) Therapeutic Dose Recommendation Level of Evidence Clinical Relevance
PM (2 inactive alleles) None. Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. Clinical effect (NS). Kinetic effect (NS).
IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele) None. Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. Clinical effect (NS). Kinetic effect (NS).
UM (gene duplication in absence of inactive or decreased activity alleles) None. None. None.
Allele Type Alleles
active *1, *2, *33, *35
decreased activity *9, *10, *17, *29, *36, *41
inactive *3-*8, *11-*16, *19-*21, *38, *40, *42
  • *See Methods or PMID: 18253145 for definition of "moderate" quality.
  • NS: not statistically significant difference.

PharmGKB gathers information regarding PGx on FDA drug labels from the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels", and from FDA-approved FDA and EMA-approved (European Medicines Agency) EMA labels brought to our attention. Excerpts from the label and downloadable highlighted label PDFs are manually curated by PharmGKB.

Please note that some drugs may have been removed from or added to the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" without our knowledge. We periodically check the table for additions to this table and update PharmGKB accordingly.

There is currently no such list for European drug labels - we are working with the EMA to establish a list of European Public Assessment Reports (EPAR)s that contain PGx information. We are constructing this list by initially searching for drugs for which we have PGx-containing FDA drug labels - of these 44 EMA EPARs were identified and are being curated for pgx information.

We welcome any information regarding drug labels containing PGx information approved by the FDA, EMA or other Medicine Agencies around the world - please contact feedback.



last updated 12/17/2013

FDA Label for fluoxetine, olanzapine and CYP2D6

Informative PGx

Summary

Symbyax, a drug mixture of fluoxetine and olanzapine, is used for the treatment of bipolar disorder and treatment resistant depression and, due to its potent CYP2D6 inhibition as a result of fluoxetine, exhibits drug interactions with other medications also metabolized by CYP2D6. Coadministration with other drugs that are metabolized by CYP2D6 should be approached with caution.

Annotation

Symbyax is a drug mixture of fluoxetine and olanzapine used for the treatment of bipolar disorder and treatment resistant depression. Fluoxetine is a selective serotonin reuptake inhibitor and is metabolized by several cytochrome P450 enzymes with CYP2D6 being a major contributor (see Fluoxetine Pathway and CYP2D6 VIP for more details). Olanzapine is an atypical antipsychotic metabolized by CYP1A2. Clearance of olanzapine is influenced by smoking (see CYP1A2 VIP for additional information).

Excerpt from the Fluoxetine and Olanzapine (Symbyax) drug label:

A subset (about 7%) of the population has reduced activity of the drug metabolizing enzyme CYP2D6. Such individuals are referred to as "poor metabolizers" of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants (TCAs). In a study involving labeled and unlabeled enantiomers administered as a racemate, these individuals metabolized S-fluoxetine at a slower rate and thus achieved higher concentrations of S-fluoxetine. Consequently, concentrations of S-norfluoxetine at steady state were lower.

Because the metabolism of fluoxetine, like that of a number of other compounds including TCAs and other selective serotonin antidepressants, involves the CYP2D6 system, concomitant therapy with drugs also metabolized by this enzyme system (such as the TCAs) may lead to drug interactions.

Fluoxetine inhibits the activity of CYP2D6 and may make individuals with normal CYP2D6 metabolic activity resemble a poor metabolizer. Coadministration of fluoxetine with other drugs that are metabolized by CYP2D6... should be approached with caution.

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Fluoxetine and Olanzapine drug label.

*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.

Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Bipolar Disorder
    • Indications & usage section, Dosage & administration section, Adverse reactions section, Clinical studies section, Use in specific populations section, Warnings and precautions section
    • source: FDA Label
  • Depression
    • Indications & usage section, Dosage & administration section, Adverse reactions section, Clinical studies section, Use in specific populations section, Warnings and precautions section
    • source: FDA Label
  • CYP1A2
    • Drug interactions section, Clinical pharmacology section, dosage, metabolism/PK
    • source: FDA Label
  • CYP2D6
    • Contraindications section, Drug interactions section, Clinical pharmacology section, Warnings and precautions section, dosage, metabolism/PK
    • source: FDA Label
  • CYP3A
    • Drug interactions section, metabolism/PK
    • source: FDA Label

last updated 10/27/2013

European Medicines Agency (EMA) Label for olanzapine and CYP1A2, CYP2D6

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for olanzapine (Zalasta) contains information regarding the metabolism of the drug by the enzymes CYP1A2 and CYP2D6: factors that induce or inhibit CYP1A2 may alter the concentration of olanzapine and thus may require dosage monitoring. The EPAR does not mention pharmacogenetics or testing of genetic variants in these genes.

Annotation

The CYP2D6 inhibitor fluoxetine is noted not to have a significant effect on olanzapine pharmacokinetics.

Excerpts from the olanzapine (Zalasta) EPAR:

Inhibition of CYP1A2 Fluvoxamine, a specific CYP 1A2 inhibitor, has been shown to significantly inhibit the metabolism of olanzapine. The mean increase in olanzapine Cmax following fluvoxamine was 54% in female non-smokers and 77% in male smokers. The mean increase in olanzapine AUC was 52% and 108% respectively. A lower starting dose of olanzapine should be considered in patients who are using fluvoxamine or any other CYP1A2 inhibitors, such as ciprofloxacin. A decrease in the dose of olanzapine should be considered if treatment with an inhibitor of CYP 1A2 is initiated.


Fluoxetine (a CYP2D6 inhibitor), single doses of antacid (aluminium, magnesium) or cimetidine have not been found to significantly affect the pharmacokinetics of olanzapine.

This information is highlighted in the following sections:
Interaction with other medicinal products and other forms of interaction, pharmacokinetic properties.

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the olanzapine EMA drug label.

*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?
GenoChip CYP2D6 (PharmGenomics, GmbH) CYP2D6*5 , rs59421388 , rs28371725 , rs5030867 , rs5030656 , rs35742686 , rs3892097 , rs5030865 , rs5030655 , rs28371706 , rs5030863 , rs1065852 , CYP2D6 *xN (gene duplication)

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP1A2 *1A N/A N/A N/A
No VIP available No VIP available VA CYP1A2 *1C N/A N/A N/A
No VIP available No VIP available VA CYP1A2 *1F N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *3 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *6 N/A N/A N/A
No VIP available CA VA CYP2D6 *1 N/A N/A N/A
No VIP available CA VA CYP2D6 *3 N/A N/A N/A
No VIP available CA VA CYP2D6 *4 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *10 N/A N/A N/A
No VIP available No VIP available VA CYP3A4 *1 N/A N/A N/A
No VIP available No VIP available VA CYP3A4 *1B N/A N/A N/A
No VIP available No VIP available VA CYP3A5 *1A N/A N/A N/A
No VIP available No VIP available VA CYP3A5 *3A N/A N/A N/A
No VIP available No VIP available VA HTR2C 2--1--1 N/A N/A N/A
No VIP available CA VA SLC6A4 HTTLPR long form (L allele) N/A N/A N/A
No VIP available CA VA SLC6A4 HTTLPR short form (S allele) N/A N/A N/A
No VIP available No VIP available VA TPMT *1 N/A N/A N/A
No VIP available No VIP available VA TPMT *3A N/A N/A N/A
No VIP available No VIP available VA TPMT *3C N/A N/A N/A
No VIP available No VIP available VA UGT1A1 *1 N/A N/A N/A
No VIP available No VIP available VA UGT1A1 *28 N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2D6 poor metabolizer N/A N/A N/A
No VIP available CA VA
rs10042486 13855688C>T, 1791G>A, 63261329C>T
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs10214163 25888769C>T, 75294410C>T
C > T
Not Available
No VIP available CA VA
rs10423928 1152+820T>A, 18450522T>A, 46182304T>A
T > A
Intronic
No VIP available No Clinical Annotations available VA
rs1045642 208920T>A, 208920T>C, 25171488A>G, 25171488A>T, 3435T>A, 3435T>C, 87138645A>G, 87138645A>T, ABCB1*6, ABCB1: 3435C>T, ABCB1: C3435T, ABCB1: c.3435C>T, ABCB1:3435C>T, Ile1145=, Ile1145Ile, MDR1 3435C>T, MDR1 C3435T, PGP C3435T, c.3435C>T, mRNA 3853C>T
A > T
A > G
Synonymous
Ile1145Ile
No VIP available No Clinical Annotations available VA
rs10458360 10791G>C, 172633975G>C, 24122617G>C, 451+445G>C
G > C
Intronic
No VIP available No Clinical Annotations available VA
rs1049353 1260G>A, 1359G>A, 26973469C>T, 88853635C>T, Thr420=, Thr453=
C > T
Synonymous
Thr453Thr
No VIP available CA VA
rs1079598 -31-870T>C, 113296274A>G, 16858690A>G, 54728T>C
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs11111201 102588475G>A, 1264-615G>A, 64731781G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs11240594 1293+104C>T, 205896235G>A, 57384877G>A
G > A
Intronic
No VIP available CA VA
rs1124493 1052-653A>C, 113282295T>G, 1139-653A>C, 16844711T>G, 68707A>C
T > G
Intronic
No VIP available No Clinical Annotations available VA
rs11631682 45846915G>A, 75056358G>A
G > A
Not Available
No VIP available No Clinical Annotations available VA
rs11677416 113529240T>C, 3277903T>C
T > C
Not Available
No VIP available CA VA
rs11872992 -1005C>T, 4415C>T, 58040587G>A, 5831451G>A
G > A
5' Flanking
No VIP available CA VA
rs11960832 26109345C>T, 75514986C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs12535293 34469G>A, 37487947G>A, 865+582G>A, 99455104G>A
G > A
Intronic
No VIP available CA VA
rs12720462 -69C>A, 171217691C>A, 22706333C>A
C > A
5' UTR
No VIP available CA VA
rs13429709 13207378T>C, 162997960T>C
T > C
Not Available
No VIP available CA VA
rs1414334 114138144C>G, 324594C>G, 456-3008C>G, 551-3008C>G, 570476C>G
C > G
Intronic
No VIP available No Clinical Annotations available VA
rs1492899 172615395C>T, 24104037C>T
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs1695 12658484A>G, 313A>G, 6624A>G, 67352689A>G, GSTP1*2, GSTP1*B, GSTP1: I105V, GSTP1:A313G, GSTP1:I105V, GSTP1:Ile105Val, Ile105Val, Part of haplotypes GSTP1*B and GSTP1*C, rs1695:A>G
A > G
Missense
Ile105Val
No VIP available No Clinical Annotations available VA
rs17070785 302+27336T>C, 4457528A>G, 4467528A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs17161981 1253+983G>A, 1254-712G>A, 1254-715G>A, 37493288G>A, 39810G>A, 99460445G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs17161983 *194A>G, *280A>G, 37496661A>G, 43183A>G, 99463818A>G
A > G
3' UTR
No VIP available No Clinical Annotations available VA
rs17782313 5641961T>C, 57851097T>C
T > C
Not Available
No VIP available CA VA
rs1799732 -487_-486insC, 113346252_113346253insG, 16908668_16908669insG, 4749_4750insC, DRD2: -141C Ins/Del
- > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs1799735 110280254delC, 110280254delCinsCCT, 3-bp deletion, 468+24delG, 468+24delGinsAGG, 702+24delG, 702+24delGinsAGG, 80252172delC, 80252172delCinsCCT, GSTM3, intron 6, rs1799735:AGG/-
C > CCT
C > -
Intronic
No VIP available No Clinical Annotations available VA
rs1799978 -585A>G, 113346351T>C, 16908767T>C, 4651A>G, DRD2: -241A>G, DRD2:A-241G
T > C
5' Flanking
No VIP available CA VA
rs1800497 113270828G>A, 16833244G>A, 17316G>A, 2137G>A, 32806C>T, DRD2 Taq1A, DRD2:32806C>T, DRD2:Taq1A, DRD2:Taq1A A1, DRD2:TaqIA allele, Glu713Lys, Taq1A
G > A
Missense
Glu713Lys
No VIP available No Clinical Annotations available VA
rs1801028 113283484G>C, 16845900G>C, 67518C>G, 845C>G, 932C>G, DRD2:1097C>G, DRD2:Ser311Cys, Ser282Cys, Ser311Cys
G > C
Missense
Ser282Cys
No VIP available No Clinical Annotations available VA
rs1801282 -2-28078C>G, 12333125C>G, 12393125C>G, 34C>G, 68777C>G, PPARG: Pro12Ala, Pro12Ala
C > G
Intronic
Pro12Ala
No VIP available No Clinical Annotations available VA
rs1880676 -68-431G>A, -90G>A, 11977G>A, 1628581G>A, 19G>A, 287-431G>A, 50824117G>A, Asp7Asn
G > A
Intronic
Asp7Asn
No VIP available No Clinical Annotations available VA
rs1995381 26165017A>G, 75570658A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs2011425 134219T>G, 142T>G, 234627608T>G, 573867T>G, 60+25097T>G, 855+36170T>G, 855+46173T>G, 856-48072T>G, 861+25097T>G, 867+5104T>G, Leu48Val
T > G
Intronic
Leu48Val
No VIP available No Clinical Annotations available VA
rs2069522 -2015T>C, 29351T>C, 45829790T>C, 75039233T>C
T > C
5' Flanking
No VIP available No Clinical Annotations available VA
rs2069526 -10+103T>G, 31459T>G, 45831898T>G, 739T>G, 740T>G, 75041341T>G, CYP1A2*1E
T > G
Intronic
No VIP available No Clinical Annotations available VA
rs2112865 26023962A>G, 75429603A>G
A > G
Not Available
No VIP available No Clinical Annotations available VA
rs221253 *1236A>C, *1236A>G, 1053311A>C, 1053311A>G, 157332172T>C, 157332172T>G, 2961538T>C, 2961538T>G
T > G
T > C
3' UTR
No VIP available No Clinical Annotations available VA
rs2213712 172599878G>C, 24088520G>C
G > C
Not Available
No VIP available No Clinical Annotations available VA
rs2228622 414G>A, 4554432G>A, 4564432G>A, 79006G>A, Exon 4, SLC1A1:rs2228622G>A, SNP2, Thr138=, syn
G > A
Synonymous
Thr138Thr
No VIP available No Clinical Annotations available VA
rs2247408 -325+3344A>G, -5+3344A>G, 112474A>G, 144278262T>C, 48447719T>C
T > C
Intronic
No VIP available CA VA
rs2266780 171083242A>G, 22571884A>G, 28225A>G, 923A>G, Glu308Gly
A > G
Missense
Glu308Gly
No VIP available CA VA
rs2268639 1224+2107T>A, 38990622T>A, 39050622T>A
T > A
Intronic
No VIP available No Clinical Annotations available VA
rs2270927 26186069C>G, 75591710C>G
C > G
Not Available
No VIP available No Clinical Annotations available VA
rs2412459 11086516C>T, 3357+444C>T, 40295959C>T
C > T
Intronic
No VIP available CA VA
rs2440390 113286878T>C, 16849294T>C, 533-545A>G, 64124A>G
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs2472297 17998C>T, 45818437C>T, 75027880C>T
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs2472300 24027A>G, 45824466A>G, 75033909A>G
A > G
Not Available
No VIP available CA VA
rs2497538 113968341C>A, 154791C>A, 349+2325C>A, 400673C>A
A > C
Intronic
No VIP available No Clinical Annotations available VA
rs2525557 -186A>G, 37611042A>G, 99578199A>G
A > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs2527887 37583797T>A, 99550954T>A
T > A
Not Available
No VIP available No Clinical Annotations available VA
rs2527894 37571684A>G, 99538841A>G
A > G
Not Available
No VIP available No Clinical Annotations available VA
rs2527927 37510269G>A, 99477426G>A
G > A
Not Available
No VIP available No Clinical Annotations available VA
rs25531 -1936A>G, 28564346T>C, 3301340T>C, 3609A>G
T > C
5' Flanking
No VIP available No Clinical Annotations available VA
rs2572023 230T>C, 37507270A>G, 99474427A>G, Ile77Thr
A > G
Missense
Ile77Thr
No VIP available No Clinical Annotations available VA
rs2734841 1052-134T>G, 113281776A>C, 1139-134T>G, 16844192A>C, 69226T>G
A > C
Intronic
No VIP available No Clinical Annotations available VA
rs2734842 *1175C>G, 113280274G>C, 16842690G>C, 70728C>G
G > C
3' Flanking
No VIP available CA VA
rs2842030 -1449G>T, 14529137G>T, 163040495G>T, 335+1177G>T, 44+1177G>T, 7100G>T
G > T
Intronic
No VIP available No Clinical Annotations available VA
rs2859228 172613241A>G, 24101883A>G
A > G
Not Available
No VIP available No Clinical Annotations available VA
rs2859229 172615017C>T, 24103659C>T
C > T
Not Available
No VIP available CA VA
rs324420 15823C>A, 16842679C>A, 385C>A, 46870761C>A, C385A, FAAH:385C>A, FAAH:Pro129Thr, Pro129Thr
C > A
Missense
Pro129Thr
No VIP available No Clinical Annotations available VA
rs3780412 4562480T>C, 4572480T>C, 767+92T>C, 87054T>C, Intron 7, SLC1A1:rs3780412A>G, SNP4
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs3780413 4557353C>G, 4567353C>G, 484-316C>G, 81927C>G, Intron 5, SLC1A1:rss3780413C>G, SNP3
C > G
Intronic
No VIP available No Clinical Annotations available VA
rs3810950 112G>A, 12479G>A, 1629083G>A, 358G>A, 4G>A, 50824619G>A, Ala120Thr, Ala2Thr, Ala38Thr
G > A
Missense
Ala120Thr
No VIP available No Clinical Annotations available VA
rs3813928 -1088G>A, -995, -997G>A, 113818282G>A, 250614G>A, 4732G>A, HTR2C c.-995G>A
G > A
5' Flanking
No VIP available CA VA
rs3813929 -759, -759C>T, -850C>T, 113818520C>T, 250852C>T, 4970C>T, HTR2C:, HTR2C: -759C/T
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs3819811 -325+1077T>C, -5+1077T>C, 110207T>C, 144280529A>G, 48449986A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs4410790 17274577T>C, 17284577T>C
T > C
Not Available
No VIP available No Clinical Annotations available VA
rs4436578 -31-11361G>A, 113306765C>T, 16869181C>T, 44237G>A
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs4580760 26034714A>C, 75440355A>C
A > C
Not Available
No VIP available No Clinical Annotations available VA
rs4646425 33399C>T, 45833838C>T, 75043281C>T, 832-249C>T
C > T
Intronic
VIP No Clinical Annotations available No Variant Annotations available
rs4680 1-5G>A, 19951271G>A, 27009G>A, 3103421G>A, 322G>A, 472G>A, COMP: Val158Met, COMT:Val108Met, Val108Met, Val158Met
G > A
5' Flanking
Val158Met
No VIP available No Clinical Annotations available VA
rs472660 1253+645G>A, 37492950G>A, 39472G>A, 99460107G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs4729562 37616493G>A, 99583650G>A
G > A
Not Available
No VIP available CA VA
rs4731426 -29+711G>C, 127882070G>C, 5740G>C, 65914913G>C
G > C
Intronic
No VIP available CA VA
rs4994 190T>C, 25681944A>G, 37823798A>G, 5387T>C, ADRB3 T727C, ADRB3:Trp64Arg, Trp64Arg
A > G
Missense
Trp64Arg
No VIP available CA VA
rs518147 -697G>C, -788G>C, 113818582G>C, 250914G>C, 5032G>C, HTR2C: -697G/C
C > G
5' UTR
No VIP available CA VA
rs5443 10501C>T, 47295C>T, 6894875C>T, 6954875C>T, 825C>T, GNB3:825C>T, GNB3:Ser275Ser, Ser275=
C > T
Synonymous
Ser275Ser
No VIP available No Clinical Annotations available VA
rs6002616 21895248A>G, 26716A>G, 42504679A>G, 535T>C, 668-15373A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs6275 113283477A>G, 16845893A>G, 67525T>C, 852T>C, 939T>C, His284=, His313=
A > G
Synonymous
His284His
No VIP available CA VA
rs6277 113283459G>A, 16845875G>A, 67543C>T, 870C>T, 957C>T, C957T, DRD2: C957T, DRD2:1035C>T, DRD2:1122C>T, DRD2:957C>T, Pro290=, Pro319=
G > A
Synonymous
Pro290Pro
No VIP available No Clinical Annotations available VA
rs6279 *376C>G, 113281073G>C, 16843489G>C, 69929C>G
G > C
3' UTR
No VIP available CA VA
rs6280 113890815C>T, 12085G>A, 20385961C>T, 25G>A, DRD3 Ser9Gly, DRD3 rs6280, DRD3: 9 Ser>Gly, DRD3: Gly9Ser, DRD3: Ser9Gly, DRD3:Ser9Gly, Gly9Ser, c.25T>C, p.S9G
C > T
Missense
Gly9Ser
No VIP available CA VA
rs6313 102C>T, 160+869C>T, 28449940G>A, 47469940G>A, 6230C>T, HTR2A:102C>T, HTR2A:T102C, Ser34=
G > A
Intronic
Ser34Ser
No VIP available CA VA
rs6318 113965735G>C, 152185G>C, 398067G>C, 68G>C, Cys23Ser, HTR2C:23Ser, HTR2C:Cys23Ser
C > G
Missense
Cys23Ser
No VIP available No Clinical Annotations available VA
rs651430 37462686A>G, 71+4034A>G, 9208A>G, 99429843A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs6874435 26169214A>G, 75574855A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs6960542 37616062C>T, 99583219C>T
C > T
Not Available
rs762551 -9-154C>A, 32035C>A, 45832474C>A, 75041917C>A, CYP1A2*1F, CYP1A2:734C>A
C > A
Intronic
No VIP available CA VA
rs7877 *207C>T, 171254890C>T, 22743532C>T
C > T
3' UTR
No VIP available No Clinical Annotations available VA
rs7912580 14720436G>A, 63915972G>A
G > A
Not Available
No VIP available No Clinical Annotations available VA
rs7973796 102596123G>A, 64739429G>A
G > A
Not Available
No VIP available CA VA
rs7997012 28391985A>G, 362-2211T>C, 47411985A>G, 5-HTR2A intron 2 variant, 614-2211T>C, 64185T>C
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs806378 -206-2026G>A, -63-4495G>A, 26979385C>T, 88859551C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs929087 172632057A>G, 24120699A>G, 395-1417A>G, 8873A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs9306356 21957659T>C, 42567090T>C, 49356A>G, 5750-1188A>G, 76963T>C
T > C
Intronic
No VIP available CA VA
rs951439 14522333C>T, 163033691C>T, 296C>T
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs9852 *68C>T, 38139024C>T, 5298386C>T
C > T
3' UTR
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • olanzapine
Trade Names
  • Olansek
  • Symbyax
  • Zalasta
  • Zydis
  • Zyprexa
  • Zyprexa Intramuscular
  • Zyprexa Zydis
Brand Mixture Names

PharmGKB Accession Id:
PA450688

Description

Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.

Source: Drug Bank

Indication

For the acute and maintenance treatment of schizophrenia and related psychotic disorders, as well as acute treatment of manic or mixed episodes of bipolar 1 disorder. Intramuscular olanzapine is indicated for the rapid control of agitated patients.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Olanzapine's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.

Source: Drug Bank

Pharmacology

Olanzapine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, olanzapine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT 2) receptors.

Source: Drug Bank

Food Interaction

Avoid alcohol.|Take without regard to meals.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic

Source: Drug Bank

Protein Binding

93%

Source: Drug Bank

Absorption

Well absorbed, with approximately 40% of the dose metabolized before reaching the systemic circulation.

Source: Drug Bank

Half-Life

21 to 54 hours

Source: Drug Bank

Toxicity

Symptoms of an overdose include tachycardia, agitation, dysarthria, decreased consciousness and coma. Death has been reported after an acute overdose of 0.45g, but also survival after an acute overdose of 1500g.

Source: Drug Bank

Clearance

  • 12 to 47 L/h

Source: Drug Bank

Route of Elimination

It is eliminated extensively by first pass metabolism, with approximately 40% of the dose metabolized before reaching the systemic circulation. Following a single oral dose of 14C labeled olanzapine, 7% of the dose of olanzapine was recovered in the urine as unchanged drug, indicating that olanzapine is highly metabolized.

Source: Drug Bank

Volume of Distribution

  • 1000 L

Source: Drug Bank

Chemical Properties

Chemical Formula

C17H20N4S

Source: Drug Bank

Isomeric SMILES

Cc1cc2c(s1)Nc3ccccc3N=C2N4CCN(CC4)C

Source: OpenEye

Canonical SMILES

CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2

Source: Drug Bank

Average Molecular Weight

312.432

Source: Drug Bank

Monoisotopic Molecular Weight

312.14086735

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ADRA1A (source: Drug Bank)
ADRA1B (source: Drug Bank)
ADRA2A (source: Drug Bank)
ADRA2B (source: Drug Bank)
ADRA2C (source: Drug Bank)
CHRM1 (source: Drug Bank)
CHRM2 (source: Drug Bank)
CHRM3 (source: Drug Bank)
CHRM4 (source: Drug Bank)
CHRM5 (source: Drug Bank)
DRD1 (source: Drug Bank)
DRD2 (source: Drug Bank)
DRD3 (source: Drug Bank)
DRD4 (source: Drug Bank)
DRD5 (source: Drug Bank)
HRH1 (source: Drug Bank)
HTR1A (source: Drug Bank)
HTR1B (source: Drug Bank)
HTR1D (source: Drug Bank)
HTR1E (source: Drug Bank)
HTR2A (source: Drug Bank)
HTR2C (source: Drug Bank)
HTR3A (source: Drug Bank)
HTR6 (source: Drug Bank)
HTR7 (source: Drug Bank)

Drug Interactions

Drug Description
olanzapine Possible antagonism of action (source: Drug Bank)
olanzapine Possible antagonism of action (source: Drug Bank)
olanzapine Fluvoxamine increases the effect and toxicity of olanzapine (source: Drug Bank)
olanzapine Fluvoxamine increases the effect and toxicity of olanzapine (source: Drug Bank)
olanzapine Possible antagonism of action (source: Drug Bank)
olanzapine Possible antagonism of action (source: Drug Bank)
donepezil Possible antagonism of action (source: Drug Bank)
donepezil Possible antagonism of action (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of olanzapine (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of olanzapine (source: Drug Bank)
galantamine Possible antagonism of action (source: Drug Bank)
galantamine Possible antagonism of action (source: Drug Bank)
ritonavir Ritonavir decreases the effect of olanzapine (source: Drug Bank)
ritonavir Ritonavir decreases the effect of olanzapine (source: Drug Bank)
rivastigmine Possible antagonism of action (source: Drug Bank)
rivastigmine Possible antagonism of action (source: Drug Bank)
olanzapine The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Olanzapine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents. (source: Drug Bank)
olanzapine The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Olanzapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents. (source: Drug Bank)
olanzapine May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. (source: Drug Bank)
olanzapine Trimethobenzamide and Olanzapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects. (source: Drug Bank)
olanzapine Triprolidine and Olanzapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects. (source: Drug Bank)
olanzapine Triprolidine and Olanzapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects. (source: Drug Bank)
olanzapine Trospium and Olanzapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to olanzapine: 92

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment. Pharmacogenetics and genomics. 2014. Drago Antonio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
No influence of CYP3A43 rs472660G>A on steady-state serum olanzapine concentrations in White psychiatric patients. Pharmacogenetics and genomics. 2014. Söderberg Mao M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain. Pharmacogenomics. 2014. Brandl Eva J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of olanzapine metabolism. Pharmacogenomics. 2013. Söderberg Mao Mao, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers. Pharmacogenomics. 2013. López-Rodríguez Rosario, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE Study. Schizophrenia research. 2013. Ramsey Timothy L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Human psychopharmacology. 2013. Cabaleiro Teresa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure. Pharmacogenetics and genomics. 2013. Söderberg Mao M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain. Human psychopharmacology. 2013. Brandl Eva J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients. The pharmacogenomics journal. 2012. Söderberg M M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genetic testing and molecular biomarkers. 2012. Müller Daniel J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Targeted pharmacogenetic analysis of antipsychotic response in the CATIE study. Pharmacogenomics. 2012. Liu Qian, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. The Journal of clinical psychiatry. 2012. Houston John P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
UGT1A4*3 Encodes Significantly Increased Glucuronidation of Olanzapine in Patients on Maintenance Treatment and in Recombinant Systems. Clinical pharmacology and therapeutics. 2012. Haslemo T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. European archives of psychiatry and clinical neuroscience. 2012. Crisafulli Concetta, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene. The pharmacogenomics journal. 2012. Chowdhury N I, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. The pharmacogenomics journal. 2012. Almoguera B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review. Pharmacogenomics. 2011. Risselada Arne J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. Pharmacogenomics. 2011. Zhang Xiang Rong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. Journal of medicinal chemistry. 2011. Kido Yasuto, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between the GIPR gene and the insulin level after glucose loading in schizophrenia patients treated with olanzapine. The pharmacogenomics journal. 2011. Ono S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Molecular psychiatry. 2011. Bigos K L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting. Pharmacogenomics. 2011. Gregoor Jochem G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Receptor targets for antidepressant therapy in bipolar disorder: An overview. Journal of affective disorders. 2011. Fountoulakis Konstantinos N, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women. Psychiatry research. 2011. Houston John, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2011. McClay Joseph L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. The pharmacogenomics journal. 2011. Kuzman M R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
KCNH2 pharmacogenomics summary. Pharmacogenetics and genomics. 2010. Oshiro Connie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia. The pharmacogenomics journal. 2010. Liu W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics. 2010. Sicard Michelle N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide association study of antipsychotic-induced QTc interval prolongation. The pharmacogenomics journal. 2010. Aberg K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Weight gain related to treatment with atypical antipsychotics is due to activation of PKC-beta. The pharmacogenomics journal. 2010. Pavan C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenetics and genomics. 2010. Lencz Todd, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. The pharmacogenomics journal. 2010. Liou Y-J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain. Journal of clinical psychopharmacology. 2010. Monteleone Palmiero, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. The pharmacogenomics journal. 2010. Müller D J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. The American journal of psychiatry. 2010. Zhang Jian-Ping, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coprescription of tamoxifen and medications that inhibit CYP2D6. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Sideras Kostandinos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenetics and genomics. 2010. Hong Chen-Jee, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2010. Tiwari Arun K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry research. 2010. Vázquez-Bourgon Javier, et al. PubMed
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. The pharmacogenomics journal. 2010. Laika B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. Pharmacology & therapeutics. 2010. Reynolds Gavin P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Archives of general psychiatry. 2009. Kwon Jun Soo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. DNA and cell biology. 2009. Herken Hasan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene. The pharmacogenomics journal. 2009. Godlewska B R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. Pharmacogenomics. 2009. Sickert Laertes, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer's disease: a 3-year follow-up longitudinal study. Journal of Alzheimer's disease : JAD. 2009. Angelucci Francesco, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenetics and genomics. 2009. Calarge Chadi A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3'-untranslated region. The pharmacogenomics journal. 2009. Greenbaum L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. Journal of psychiatric research. 2009. Shen Yu-Chih, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. The pharmacogenomics journal. 2009. Popp J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Correlates of response to Olanzapine in a North Indian Schizophrenia sample. Psychiatry research. 2008. Thomas Pramod, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. Journal of psychiatric research. 2008. Alenius Malin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. The Journal of clinical psychiatry. 2008. Ujike Hiroshi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes. Pharmacogenomics. 2008. Srivastava Vibhuti, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder. Human psychopharmacology. 2008. Adams David H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. The pharmacogenomics journal. 2008. Smith R C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Therapeutic drug monitoring. 2008. Nozawa Motohiro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. Biological psychiatry. 2008. Campbell Daniel B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophrenia research. 2008. de Leon Jose, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2007. Chagnon Y C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Choline acetyltransferase variants and their influence in schizophrenia and olanzapine response. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2007. Mancama D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis. Human psychopharmacology. 2007. De Luca Vincenzo, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2007. Xing Qinghe, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism. The pharmacogenomics journal. 2007. Tiwari A K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. Journal of clinical psychopharmacology. 2007. Mulder Hans, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. The pharmacogenomics journal. 2007. Theisen F M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Molecular psychiatry. 2007. Ruaño G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A clinical study of the association of antipsychotics with hyperlipidemia. Schizophrenia research. 2007. de Leon Jose, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clinical pharmacology and therapeutics. 2007. Yang S-Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Therapeutic drug monitoring. 2006. Lin Ying-Chi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. The American journal of psychiatry. 2006. Lencz Todd, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophrenia research. 2005. Bishop Jeffrey R, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology. 2005. Hwang Rudi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2005. Ellingrod Vicki L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neuroscience letters. 2005. Wu Shengnan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biological psychiatry. 2004. Weickert Thomas W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. The American journal of psychiatry. 2004. Bertolino Alessandro, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. The British journal of psychiatry : the journal of mental science. 2004. Young Ross McD, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. Journal of clinical psychopharmacology. 2003. Carrillo Juan Antonio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia. Psychopharmacology bulletin. 2003. Ellingrod Vicki L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. European journal of pharmacology. 2002. Kongsamut Sathapana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatric genetics. 2002. Ellingrod Vicki L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Med-psych drug-drug interactions update. Psychosomatics. 2002. Armstrong Scott C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. European journal of clinical pharmacology. 2001. Hägg S, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics. 2001. Suzuki A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Science, medicine, and the future: Pharmacogenetics. BMJ (Clinical research ed.). 2000. Wolf C R, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics. 1998. Arranz M J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia. Psychiatry research. 1998. Ohara K, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0002-4112-30
DrugBank:
DB00334
ChEBI:
7735
KEGG Compound:
C07322
KEGG Drug:
D00454
PubChem Compound:
4585
PubChem Substance:
197059
IUPHAR Ligand:
47
Drugs Product Database (DPD):
2247099
BindingDB:
35254
Therapeutic Targets Database:
DAP000022
FDA Drug Label at DailyMed:
d5051fbc-846b-4946-82df-341fb1216341

Clinical Trials

These are trials that mention olanzapine and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.